ÁñÁ«ÊÓƵ

This study examines the strength of association between surrogate markers used as primary end points in clinical trials to support FDA approval of drugs treating nononcologic chronic diseases and clinical outcomes.

This study examines whether payments from a left ventricular assist device manufacturer to cardiologists performing percutaneous coronary intervention were associated with any use of the devices.

This cross-sectional study evaluates the use of the US Food and Drug Administration’s Real-Time Oncology Review (RTOR) program in confirming the effectiveness of cancer drugs.

This study examines the distribution of payments within and across specialties and the medical products associated with the largest total payments.

This Viewpoint describes implications for medicine and public health if the US Supreme Court decides to overturn or narrow Chevron deference.

This cross-sectional study of US hospitals compared hospital and patient characteristics to evaluate equitable rates of readmission by insurance (dual eligible [Medicare and Medicaid] vs non–dual eligible) and race (Black vs White).

This cross-sectional study characterizes the frequency and degree of innovation of new dermatologic drugs approved by the US Food and Drug Administration (FDA) from 2012 to 2022.

This study evaluates whether FDA-approved novel cancer therapeutics supported by pivotal trials with adequate representation of minoritized groups were associated with slower clinical development times than those with inadequate representation.

This study explores the ways new device authorization and coverage are expedited by the US Food and Drug Administration and Centers for Medicare & Medicaid Services, using examples of devices granted Breakthrough designation, and recommends reforms that both agencies should consider.

This cross-sectional study evaluates the supporting clinical trials for supplemental new drug applications and supplemental biologics license applications from 2017 to 2019.

This systematic review and meta-analysis investigates the association of mortality, poor functional outcomes, recurrent stroke, and dementia in patients with poststroke seizures compared with patients without poststroke seizures.

This Viewpoint discusses the next steps to realize the public health promise of using unique device identifiers in health information data and outlines the progress and challenges in implementation over the past 10 years.

This study reviewed public comments for all Medicare National Coverage Determinations between June 2019 and 2022 on select pulmonary and cardiac devices to determine whether financial conflicts of interest were disclosed.

This cross-sectional study evaluates the duration between application to US Food and Drug Administration (FDA) and approval for new drugs and biologics in the US from 2015 to 2022.

This cross-sectional study examines the ties between pharmaceutical and medical device industries and the executive leadership of the 50 highest-revenue US-based patient advocacy organizations.

This cross-sectional study investigates rates of results reporting among oncology clinical trials across trial registries, medical journals, and medical conferences.